PBYI
Puma Biotechnology, Inc.
NASDAQ · USHealthcareBiotechnology
$8.30-2.70%
Price as of Jul 20, 2026
PBYI financials
Puma Biotechnology, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M |
| Cost of revenue | $58.2M | $64.4M | $62.7M | $55.1M |
| Gross profit | $170.2M | $166.1M | $173.0M | $172.9M |
| Operating expenses | $132.9M | $135.1M | $140.3M | $149.2M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M |
| Net income | $31.1M | $30.3M | $21.6M | $2.0K |
| EBITDA | $53.3M | $48.1M | $47.5M | $21.9M |
| Basic EPS | $0.62 | $0.62 | $0.46 | $0.02 |
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.02 |
| Balance sheet | ||||
| Cash & equivalents | $29.6M | $69.2M | $84.6M | $76.2M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M |
| Stockholders’ equity | $130.3M | $92.1M | $53.4M | $21.6M |
| Total debt | $28.5M | $74.1M | $111.5M | $114.3M |
| Net debt | -$1.1M | $4.9M | $26.9M | $38.1M |
| Cash flow | ||||
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M |
| Capital expenditure | -$71.0K | -$56.0K | -$12.6M | -$7.0M |
| Free cash flow | $41.7M | $38.9M | $14.4M | -$22.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |